Alvotech Shares Plunge 33% After FDA Flags Issues

Alvotech (NASDAQ:ALVO) shares plummeted 33.99% after the FDA issued a Complete Response Letter (CRL) for its biosimilar candidate AVT05, a biosimilar to Johnson & Johnson's Simponi. The CRL cited unresolved deficiencies from a pre-license inspection of Alvotech's Reykjavik manufacturing facility, which must be addressed before approval. Consequently, Alvotech has lowered its 2025 revenue guidance to $570-$600 million and adjusted EBITDA to $130-$150 million, attributing the revision to ongoing facility investments and temporary production slowdowns, signaling a significant delay in market entry for a key product.

Analysis

Alvotech (NASDAQ:ALVO) shares plummeted 33.99% on Monday, trading at $5.05 with a session volume of 2.32 million, significantly above its average. This sharp decline follows the U.S. FDA's issuance of a Complete Response Letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT05, a biosimilar candidate to Johnson & Johnson’s Simponi. The CRL specifically cited unresolved deficiencies from a pre-license inspection of Alvotech's Reykjavik manufacturing facility, which must be satisfactorily resolved before approval.

The FDA's decision has prompted Alvotech to revise its 2025 financial outlook, lowering total revenue expectations to $570-$600 million and adjusted EBITDA to $130-$150 million. This downward revision is attributed to anticipated continued investments in facility remediation and a temporary slowdown in production, indicating a material delay in the market entry for AVT05. Despite the CRL, the FDA did not identify other application deficiencies, and the facility remains approved for existing commercialized products.

The delay impacts Alvotech's ability to capitalize on the U.S. Simponi market, which saw sales of less than $300 million in H1 2025, especially given the current absence of FDA-approved Simponi biosimilars. While Alvotech has submitted a comprehensive Corrective and Preventive Action (CAPA) plan, the requirement for resolution by July 2025 introduces uncertainty regarding the timeline for AVT05's potential approval and subsequent commercialization. The significant increase in trading volume alongside the price drop underscores strong negative market reaction to these regulatory and operational setbacks.

Key Decisions for Investors

• Investors should closely monitor Alvotech's progress in resolving the FDA's identified facility deficiencies and any updated timeline for AVT05's resubmission and potential approval.
• Re-evaluate financial models for ALVO, incorporating the revised 2025 revenue and EBITDA guidance and factoring in potential delays for key product launches.
• Assess the evolving competitive landscape for Simponi biosimilars, considering that the delay provides an opportunity for potential rivals to advance their own candidates.